Format

Send to

Choose Destination
Clin Infect Dis. 2016 Sep 15;63(6):e112-46. doi: 10.1093/cid/ciw360. Epub 2016 Jul 27.

2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis.

Author information

1
Valley Fever Center for Excellence.
2
Division of Infectious Diseases, University of Arizona, Tucson.
3
Division of Infectious Diseases, Mayo Clinic, Scottsdale, Arizona.
4
Division of Pulmonary and Critical Care, University of California, San Diego.
5
Department of Pediatrics, Infectious Diseases, Stanford University School of Medicine, California.
6
Division of Sanford Health, Sioux Falls, South Dakota.
7
David Geffen School of Medicine at UCLA, Department of Medicine, Kern Medical Center, Bakersfield, California.
8
Department of Rheumatology, University of Arizona, Tucson.
9
Department of Neurosurgery School of Medicine, University of Utah, Salt Lake City.
10
Division of Thoracic Surgery, Northwestern University, Feinberg School of Medicine.
11
Division of Neurosurgery, John H. Stroger Jr Hospital of Cook County, Chicago, Illinois.
12
Arizona Pulmonary Specialists, Ltd, Phoenix.
13
Division of Infectious Diseases, Stanford University School of Medicine, California.
14
Career Epidemiology Field Officer Program, Division of State and Local Readiness, Office of Public Health Preparedness and Response, Centers for Disease Control and Prevention Maricopa County Department of Public Health.
15
Department of Neurosurgery, Barrow Neurological Institute, Phoenix, Arizona.

Abstract

It is important to realize that guidelines cannot always account for individual variation among patients. They are not intended to supplant physician judgment with respect to particular patients or special clinical situations. Infectious Diseases Society of America considers adherence to these guidelines to be voluntary, with the ultimate determination regarding their application to be made by the physician in the light of each patient's individual circumstances.Coccidioidomycosis, also known as San Joaquin Valley fever, is a systemic infection endemic to parts of the southwestern United States and elsewhere in the Western Hemisphere. Residence in and recent travel to these areas are critical elements for the accurate recognition of patients who develop this infection. In this practice guideline, we have organized our recommendations to address actionable questions concerning the entire spectrum of clinical syndromes. These can range from initial pulmonary infection, which eventually resolves whether or not antifungal therapy is administered, to a variety of pulmonary and extrapulmonary complications. Additional recommendations address management of coccidioidomycosis occurring for special at-risk populations. Finally, preemptive management strategies are outlined in certain at-risk populations and after unintentional laboratory exposure.

KEYWORDS:

antifungal treatment; coccidioidomycosis; community acquired pneumonia; immunocompromised patients; travel history

PMID:
27470238
DOI:
10.1093/cid/ciw360
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center